Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Koji Kato et al.|Nature Medicine|2021Cited by 523
Machine learning-based cytokine microarray digital immunoassay analysisYujing Song, Katsuo Kurabayashi, Jingyang Zhao et al.|Biosensors and Bioelectronics|2021Cited by 56
Cardiovascular Events After Hematopoietic Stem Cell TransplantAlexi Vasbinder, Salim S. Hayek, Christopher W. Hoeger et al.|JACC CardioOncology|2023Cited by 46
Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE‐BMT Risk ScoreAlexi Vasbinder, Salim S. Hayek, Tonimarie Catalan et al.|Journal of the American Heart Association|2023Cited by 25
138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)Catherine Thiéblemont, Nathan Fowler, M. Dreyling et al.|Hematological Oncology|2025Cited by 1